Predix Pharmaceuticals to be acquired

Predix President and CEO Dr. Michael G. Kauffman will become the CEO of the combined company.

April 5, 2006 08:15


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Ramat Gan-based Predix Pharmaceuticals Holdings, Inc. has agreed to be acquired by US-based EPIX Pharmaceuticals Inc. for $90 million, including the assumption of net debt at closing. EPIX will pay shareholders of privately held Predix approximately $35 million in cash, stock, or a combination of both, depending on the achievement of certain clinical and strategic milestones, as well as 47% of the combined company's shares outstanding. Predix President and CEO Dr. Michael G. Kauffman will become the CEO of the combined company.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection